2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2099

Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong
Abstract Number: 2100

Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients
Abstract Number: 2101

Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic
Abstract Number: 2102

First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients
Abstract Number: 2103

Anti-TNF Therapy in Patients with HIV Infection
Abstract Number: 2104

Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process
Abstract Number: 2105

The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Abstract Number: 2106

Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy
Abstract Number: 2107

Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Abstract Number: 2108

Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients
Abstract Number: 2109

Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Abstract Number: 2110

Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico
Abstract Number: 2111

Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Abstract Number: 2112

Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Abstract Number: 2113

Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].